adalimumab + certolizumab + golimumab + infliximab + natalizumab + tofacitinib + ustekinumab + vedolizumab

This is a combination of eight immunomodulatory drugs, each with distinct mechanisms of action, primarily used in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and multiple sclerosis. The drugs included are:

• Adalimumab (a monoclonal antibody targeting tumor necrosis factor alpha [TNFα])
• Certolizumab pegol (a PEGylated Fab' fragment monoclonal antibody against TNFα)
• Golimumab (a monoclonal antibody against TNFα)
• Infliximab (a chimeric monoclonal antibody against TNFα)
• Natalizumab (a monoclonal antibody targeting α4-integrin)
• Tofacitinib (an oral small molecule Janus kinase [JAK] inhibitor)
• Ustekinumab (a monoclonal antibody targeting interleukin 12 and interleukin 23)
• Vedolizumab (a gut-selective integrin α4β7 antagonist)

These agents are not typically combined in clinical practice but represent major classes of biologics and targeted therapies for immune-mediated diseases.